The gut microbiome plays an important role in nutrient metabolism and the regulation of metabolic and immune homeostasis. Increasing evidence suggests that changes in microbial composition and function, commonly described as dysbiosis, may be associated with obesity, insulin resistance, dyslipidemia, and metabolic syndrome. These effects may involve several biochemical mechanisms, including short-chain fatty acid production, bile acid metabolism, intestinal barrier integrity, and inflammatory signaling. This review examines the relationship between the gut microbiome and glucose and lipid metabolism, with particular emphasis on microbial metabolites and their potential effects on cellular signaling and insulin responsiveness. It also discusses microbiome-modulating strategies involving dietary patterns, fiber, probiotics, and prebiotics, as well as the current limitations affecting their clinical application. The evidence indicates that the relationship between the microbiome and metabolic syndrome is complex and influenced by diet, genetics, environmental exposures, and medication use. Further well-designed clinical studies are needed to establish causal relationships and determine the long-term efficacy of microbiome-targeted interventions. Keywords: Gut microbiome; insulin resistance; metabolic syndrome; short-chain fatty acids; bile acids; metabolic inflammation. 1. Introduction The gastrointestinal tract contains diverse microbial communities that contribute to the digestion of selected dietary components, the production of biologically active metabolites, and interactions with the immune system. Advances in microbiome analysis have increased scientific interest in its potential role in regulating metabolic processes beyond the gastrointestinal tract. Metabolic syndrome is characterized by a cluster of risk factors, including central obesity, abnormal glucose and lipid metabolism, and elevated blood pressure. Research has identified associations between microbial composition and several of these abnormalities. However, these associations vary among individuals and do not necessarily establish that a particular microbial change directly causes disease. 2. Gut microbiome and metabolic homeostasis The gut microbiome contributes to the breakdown of dietary compounds that are incompletely digested by human enzymes and influences the production and bioavailability of metabolites. These functions depend on multiple factors, including diet, age, medication use, health status, and individual differences in microbial communities. Dysbiosis describes changes in microbial composition or function. Nevertheless, no single microbial profile can currently be generalized to all individuals with metabolic syndrome. 3. Microbial metabolites and their mechanisms 3.1. Short-chain fatty acids Short-chain fatty acids, including acetate, propionate, and butyrate, are produced when intestinal bacteria ferment certain dietary fibers. These compounds participate in intestinal barrier regulation and influence selected cellular signaling, inflammatory, and metabolic pathways. Some of their effects may involve the regulation of gut hormone secretion and tissue insulin responsiveness. However, the biological outcomes depend on the specific fatty acid, its concentration and site of production, and the individual's metabolic condition. 3.2. Bile acid metabolism Bile acids facilitate dietary fat digestion and absorption and also act as signaling molecules through receptors such as FXR and TGR5. The gut microbiome modifies the bile acid pool, potentially affecting glucose and lipid metabolism and energy homeostasis. The precise mechanisms and clinical consequences remain under investigation. 3.3. Other microbial metabolites Gut microorganisms generate a wide range of metabolites from amino acids and other nutrients. Some may influence inflammation and metabolic regulation. Examples include tryptophan derivatives and trimethylamine N-oxide (TMAO). The concentrations of these compounds may be associated with dietary and metabolic factors, but observational associations alone do not establish causality. 4. The gut microbiome and insulin resistance Impairment of the intestinal barrier may, under certain conditions, increase the passage of microbial components, including lipopolysaccharide (LPS), into the circulation and stimulate inflammatory responses. Inflammatory signaling can affect pathways involved in insulin action and interact with metabolic functions in the liver, adipose tissue, and skeletal muscle. Although these mechanisms are supported by experimental research, the extent to which each contributes to insulin resistance in humans varies and requires careful clinical evaluation. 5. Relevant biochemical markers Studies investigating the microbiome–metabolic syndrome relationship may include: Fasting glucose and glycated hemoglobin (HbA1c). Fasting insulin and the homeostatic model assessment of insulin resistance (HOMA-IR), when appropriate to the study design. Triglycerides and high-density lipoprotein cholesterol. C-reactive protein (CRP) and selected inflammatory cytokines. Short-chain fatty acids and microbiome-derived metabolites measured using appropriate analytical methods. No single panel of microbiome metabolites is currently sufficient to diagnose metabolic syndrome or determine the appropriate treatment for every patient. 6. Potential therapeutic applications Strategies under investigation include dietary modification, increased intake of suitable dietary fibers, and selected probiotic and prebiotic interventions. Some studies have reported promising results, but outcomes vary according to microbial strain, dose, intervention duration, and participant characteristics. Fecal microbiota transplantation remains a specialized intervention requiring careful assessment of risks and benefits. It should not be regarded as routine treatment for metabolic syndrome outside established indications and approved protocols. Moreover, successfully changing microbial composition does not necessarily demonstrate sustained clinical improvement. 7. Challenges and future directions Major challenges include substantial interindividual variability, difficulties separating dietary effects from microbiome effects, and differences in sample collection and analytical methods. Future studies could combine microbiome profiling with metabolite analysis and biochemical measurements. Longitudinal investigations and well-controlled clinical trials are needed to establish causality and evaluate therapeutic outcomes. 8. Conclusions The gut microbiome is associated with important processes involved in glucose and lipid metabolism and inflammatory regulation. Microbial metabolites, including short-chain fatty acids and microbiologically modified bile acids, represent promising research pathways for understanding insulin resistance and metabolic syndrome. However, translating this knowledge into clinical applications requires further methodological standardization and validation in well-designed human studies. Al-Mustaqbal University – The First Among Private Universities in Iraq